EMD-52520

Single-particle
2.6 Å
EMD-52520
3D View Gallery
Deposition: 13/01/2025
Map released: 16/07/2025
Last modified: 30/07/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-52520
Download
3D volume (map.gz) Experimental metadata (xml) Experimental Metadata (cif.gz)
Map-only Validation report (pdf.gz) Map-only Validation report (cif.gz) Map-only Validation report (xml.gz)
Map and PDB model 9hz5 summary report (pdf.gz) Map and 9hz5 FULL report (pdf.gz)
EMICSS annotations (xml)

Pre-clinical characterization of novel multi-client inhibitors of Sec61 with broad anti-tumor activity

EMD-52520

Single-particle
2.6 Å
EMD-52520
3D View Gallery
Deposition: 13/01/2025
Map released: 16/07/2025
Last modified: 30/07/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Ovis aries
Sample: Sec61 translocon complex with small molecule
Fitted models: 9hz5

Deposition Authors: Shahid R, Paavilainen VO
Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity.
Lowe E, Anderl JL , Bade D, Delgado-Martin C, Dong C, Fan RA, Fang Y, Jiang J, Johnson HWB, Kempema A, McGilvray P, McMinn D, Millare B, Muchamuel T, Poweleit N, Qian Y, Rehan S, Scapin G, Sugahara A, Tranter D, Tuch B, Wang J, Wang L, Whang JA, Zuno-Mitchell P, Paavilainen VO, Park E, Taunton J, Kirk CJ, Anand NK
(2025) J Pharmacol Exp Ther , 392 , 103634 - 103634
PUBMED: 40669140
DOI: doi:10.1016/j.jpet.2025.103634
ISSN: 1521-0103
Grant Support: